603718 Shanghai Hile Bio-Technology
- 7.96
- -0.09-1.12%
Shanghai Hile Bio-Technology News
Hailey Biotech (603718.SH) reported 2023 results, net profit of 62.882 million yuan, a year-on-year decrease of 48.30%
Hailey Biotech (603718.SH) released its 2023 annual report, achieving revenue of 241 million yuan, a year-on-year decrease of 19.76%. Net profit attributable to shareholders of listed companies was 62.882 million yuan, a year-on-year decrease of 48.30%. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was RMB 11.8219 million, a year-on-year decrease of 52.36%. It is proposed to distribute a cash dividend of 0.287 yuan (tax included) for every 10 shares to all shareholders.
Express News | Hailey Biotech: Net loss of 3.7194 million yuan in the first quarter
A-share agricultural services continued to rise, and Hailey Biotech closed up and down
Gelonghui, March 21 | Haili Biotech closed, and Yongshun Biotech, Dayu Water Saving, Huisheng Biotech, Zhongmu Co., Ltd., and Xianfeng Holdings followed suit.
“Double random” spot checks were effective, and 8 company problems were revealed! Hailey Biotech and others announced the results of the Securities Regulatory Bureau's investigation
① Hailey Biotech announced tonight that the Shanghai Securities Regulatory Bureau has taken measures to issue a warning letter against the company and related responsible persons. ② According to an article published on the official website of the Shanghai Securities Regulatory Bureau in June last year, two random spot checks were carried out for on-site inspections of listed companies in Shanghai in 2023, and 8 random targets were selected; an article published in November last year showed that the inspection work was completed. ③ The reporter saw from the announcements of 8 listed companies that all had problems with credit disclosure.
Hailey Biotech (603718.SH) received a warning letter from the Shanghai Securities Regulatory Bureau
Hailey Biotech (603718.SH) issued an announcement. The company recently received a decision on administrative supervision measures from the Shanghai Securities Regulatory Bureau...
[BT Financial Report Instantaneous Analysis] Hailey Biotech's 2023 Quarterly Report Perspective: Seek New Opportunities Amidst Challenges, Significant Growth in Net Profit
Hailey Biotech (stock code: 603718) is a publicly traded company involved in both the veterinary biological products and in vitro diagnostic (IVD) industries. Faced with challenges such as industry reshuffling, environmental protection policies, anti-resistance measures, and African swine fever, Hailey Biotech has responded positively to maintain market competitiveness by increasing investment in R&D to improve product quality and technical service levels. At the same time, the company is also seizing the rapid development opportunities in the field of in vitro diagnostics, especially on tracks such as molecular diagnosis and POCT, and strives to enhance independent R&D and production capacity to adapt to the trend of domestic production substitution. In terms of assets and liabilities, according to the 2023 three-quarter report
Hailey Biotech (603718.SH) released the first three quarter results, net profit of 74.6985 million yuan, up 86.47% year on year
Hailey Biotech (603718.SH) released its report for the first three quarters of 2023, with revenue of 195 million yuan...
Express News | Yao Ming Hyde's first vaccine CDMO base in China officially put into operation
Hailey Biotech (603718.SH): Grants 17.9 million stock options and 13.9 million restricted shares to incentive recipients
GLONGHUI September 5 | Hailey Biotech (603718.SH) announced that the company agreed to grant 13.9 million restricted shares to 78 incentive recipients and 17.9 million stock options to 98 incentive recipients.
Hailey Biotech (603718.SH) released first-half results, net profit of 446.791 million yuan, an increase of 47.59% over the previous year
Hailey Biotech (603718.SH) released the 2023 semi-annual report. During the reporting period, the company achieved operating income...
Hailey Biotech (603718.SH): Plans to introduce 32 million restricted stock and stock options incentive plan
Glonghui, August 18: Hailey Biotech (603718.SH) announced the 2023 restricted stock and stock options incentive plan. The total number of shares to be granted to incentive recipients was 32 million shares, accounting for about 4.97% of the company's total share capital of 644 million shares at the time the draft incentive plan was announced. There were no reserved rights. The grant price was 4.78 yuan/share, and the total number of incentive recipients was 99.
Hailey Biotech (603718.SH): General manager Chen Xiao resigns and hires Han Benyi as general manager
According to the Zhitong Finance App, Hailey Biotech (603718.SH) announced that the company's board of directors recently received a report on the resignation of Chen Xiao, the company's general manager. Due to personal reasons, Chen Xiao requested to resign as the company's general manager. Following the nomination of the company's chairman and review by the nomination committee of the company's board of directors, the board of directors of the company agreed to appoint Han Benyi as the company's general manager and Chen Xiao and Liu Yanlin as the company's deputy general managers. The term of office starts from the date of review and approval by the board of directors until the end of the fourth board of directors.
Hailey Biotech (603718.SH) distributes 0.0567 yuan per share in 2022. The share registration date is July 12
According to the Zhitong Finance App, Hailey Biotech (603718.SH) announced that the company will implement the 2022 annual equity distribution, with a cash dividend of 0.0567 yuan (tax included) per share. The share registration date is July 12.
Hailey Biotech (603718.SH): Has a new veterinary drug certificate for the avian influenza DNA vaccine (H5 subtype, pH5-GD)
Glonghui, May 5 丨 An investor asked Hailey Biotech (603718.SH) on the investor interactive platform, “Does your company have any bird flu-related products?” Hailey Biotech replied that the company has a new veterinary drug certificate for the avian influenza DNA vaccine (H5 subtype, pH5-GD), but no relevant production approval has been obtained, so it has not yet been produced and sold
Hailey Biotech (603718.SH): Pharmaceutical Minghyde is mainly engaged in the vaccine CDMO business
Glonghui, May 5 丨 An investor asked Hailey Biotech (603718.SH) on the investor interactive platform, “How is the anti-cancer vaccine developed by the subsidiary Pharmaceutical Minghyde progressing, and is it undergoing clinical trials?” Hailey Biotech replied that Pharmaceutical Hyde is mainly engaged in the vaccine CDMO business. For the relevant situation, you can pay attention to the relevant regular reports disclosed by Pharmaceutical Biotech and the company.
Hailey Biotech (603718.SH): The company's subsidiaries are not involved in nucleic acid testing business
Gelonghui, May 5 丨 An investor asked Hailey Biotech (603718.SH) through SSE E-Interactive, “How is your subsidiary's nucleic acid testing business going? Does it help the company grow? Also, what direction is your company's next focus? “, Hailey Biotech (603718.SH) replied, “Dear investors, the company's subsidiaries are not involved in the nucleic acid testing business yet, and the company will continue to maintain the “mobile insurance+human insurance” two-wheel drive strategy. Thank you. “
Hailey Biotech (603718.SH) Announces 2022 Results Net Profit of 122 Million Yuan Increased by 125.8% to $0.567 per 10
According to the Zhitong Finance App, Hailey Biotech (603718.SH) revealed its 2022 annual report. The company achieved operating income of 300 million yuan during the reporting period, a year-on-year decrease of 13.62%. Net profit attributable to shareholders of listed companies was 122 million yuan, an increase of 125.80% over the previous year. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 248.14,400 yuan, an increase of 9.22% over the previous year. The basic earnings per share were 0.19 yuan/share. It is proposed to distribute a cash dividend of 0.567 yuan (tax included) for every 10 shares.
Hailey Biotech (603718.SH) announced first-quarter results, net profit of 14.24 million yuan, up 34.35% year-on-year
According to the Zhitong Finance App, Hailey Biotech (603718.SH) disclosed its report for the first quarter of 2023. The company achieved operating income of 71,234,400 yuan during the reporting period, a year-on-year decrease of 16.27%. Net profit attributable to shareholders of listed companies was 142.357 million yuan, an increase of 34.35% over the previous year. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was RMB 11.183,300, an increase of 28.64% over the previous year. Basic earnings per share were 0.022 yuan/share.
Haili Biotech (603718.SH) plans to sell 100% of Shandong Haili and Caiyin Biotech's shares for 115 million dollars to divest inefficient assets to improve overall profitability
Gelonhui, April 11丨Haili Biotech (603718.SH) announced that the company held the 12th meeting of the fourth board of directors on April 11, 2023 to deliberate and pass the “Proposal on the Sale of Shares in Shandong Haili Biological Products Co., Ltd., a wholly-owned subsidiary”. As a new production base for the company's relocation and transfer of related raw production capacity, due to the influence of the market and related policies, up to now only eight products have obtained approval numbers for new veterinary drug products, and are expected to meet the company's profit expectations in the short term. It's difficult, so it's peeling
Hailey Biotech (603718.SH): 2022 net profit is expected to increase 115.39%-158.09%
Gelonghui, January 18, 丨Haili Biotech (603718.SH) announced that the company expects net profit attributable to shareholders of listed companies in 2022 to be between 116 million yuan and 139 million yuan, an increase of 62.1433 million yuan to 85,143 million yuan over the same period of the previous year, an increase of 115.39% to 158.09% over the same period last year. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss is expected to be between 24 million yuan and 31 million yuan, an increase of 1,2812 million yuan to 8.2812 million yuan over the same period of the previous year, an increase of 5.64% to 36.45
Analysis
Price Target
No Data
